Panel Discussion: Future Directions – Where Does the Chain Break? A Collective Assessment of the Industry’s Most Critical Unresolved Supply Chain Challenges & the Priorities That Must Be Addressed Collectively Before the Next Wave of Approvals Arrives
- Across the two days, which single supply chain or manufacturing bottleneck has emerged as most urgent, and what does a credible industry-level response to it look like?
- Where does the field realistically stand on isotope supply security in five years, and which production pathways, technologies, and investment models will determine whether commercial-scale alpha therapy becomes a reality?
- How must the relationship between biopharma, CDMOs, isotope providers, logistics specialists, and clinical sites evolve structurally to one that can reliably deliver therapies to patients at scale?